Clinical Trial Update: Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer [NA]

View source ↗

Summary

Completed clinical trial evaluating cabozantinib-s-malate in hormone-resistant metastatic prostate cancer; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Cabozantinib S-Malate (cabozantinib)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | NA | Status: COMPLETED | Results posted: 2021-03-23